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Abstract
Mitochondrial phenotype is complex and difficult to define at the level of individual cell types. Newer metabolic profiling
methods provide information on dozens of metabolic pathways from a relatively small sample. This pilot study used ‘‘top-
down’’ metabolic profiling to determine the spectrum of metabolites present in liver mitochondria. High resolution mass
spectral analyses and multivariate statistical tests provided global metabolic information about mitochondria and showed
that liver mitochondria possess a significant phenotype based on gender and genotype. The data also show that
mitochondria contain a large number of unidentified chemicals.
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Introduction
Mitochondria are the main source of energy in most eukaryotic
cells. They play a vital role in ATP production via oxidative
phosphorylation and the tricarboxylic acid cycle (TCA cycle).
While energy production is a major process performed by the
mitochondrion, many other important metabolic pathways are
present. These pathways include fatty acid and amino acid
oxidation, apoptosis, and biosynthesis of ketone bodies, pyrimi-
dines, steroids, heme and urea [1]. Due to the essential role that
they play in cellular metabolism, dysfunction of this organelle can
have dire consequences.
Mitochondrial dysfunction represents a generic disease mech-
anism, i.e., if mitochondria do not function properly, disease will
result [2]. Mitochondrial dysfunction is a primary cause of many
inborn errors of metabolism. For example, Kearns-Sayre syn-
drome results from large deletions of the mitochondrial genome
and maple syrup urine disease is caused by a deficiency in
branched chain amino acid metabolism [3,4]. Mitochondrial
dysfunction can also occur as a result of a toxic insult or disease
pathogenesis. For example, the potent antineoplastic agent,
doxorubicin, can cause cardiotoxicity via oxidative stress and
redox cycling in cardiomyocyte mitochondria [5]. Additionally,
Complex I inhibition and subsequent neurotoxicity has been
implicated in pesticide-mediated Parkinson’s disease [6]. Lastly,
the mitochondrial protein, thioredoxin-2 (Trx2), is intimately
involved in the maintenance of cell viability and mitochondrial
redox potential. For example, Trx2 is a key defense mechanism
against oxidant-induced apoptosis and regulator of mitochondrial
permeability transition [7,8]. It is unknown, however, how
alterations in abundance of Trx2 will affect mitochondrial and
whole cell metabolism.
Environmental influences, including diet, chemical exposures
and lifestyle, vary widely amongst individuals. Additionally,
environmental exposures play a major role in chronic disease
[9]. Because of this, Wild [9] emphasized the need to complement
the human genome project with an effort to characterize the
spectrum of exposures that an individual experiences, the
‘‘exposome’’, and how these exposures impact disease risk.
Metabolic profiling of human plasma can give valuable informa-
tion regarding all environmental influences, in addition to genetics,
epigenetics and proteomics, affecting health outcome and disease
[10]. Common approaches employed to profile metabolites are
nuclear magnetic resonance (NMR) and mass spectrometry.
Recently, the development of high resolution, high mass accuracy
mass spectrometers, such as Fourier transform ion cyclotron
resonance (FTICR) and Orbitrap mass spectrometry, have
allowed for accurate mass determination and improved through-
put due to a decreased need for lengthy separation techniques and
ion fragmentation [10,11].
Much is known about the mitochondrial proteome [1];
however, knowledge about the spectrum of metabolites in the
mitochondria has largely been obtained from studies of specific
pathways. Targeted studies have examined changes in mitochon-
drial metabolism by analyzing peripheral fluids like urine and
plasma or whole cells in culture [12,13,14,15,16,17,18,19]. In
contrast, this ‘‘top-down’’ method of high performance metabolic
profiling [10,20] examines the array of metabolites present in
isolated mitochondria, identified in terms of high-resolution mass-
to-charge ratio (m/z) and chromatographic retention time.
Because the high-resolution m/z has sufficient mass accuracy to
predict elemental composition, and .90% of the most common
intermediary metabolites (e.g. approximately 2000 present in
human metabolomics databases) are non-redundant in elemental
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33020composition, one can match m/z and metabolic pathways, and
verify identities by MS/MS and retention time relative to
authentic standards [10,20].
In the present study, mitochondrial isolations from wild-type
and mice over-expressing the mitochondrial protein, thioredoxin-
2, were extracted using acetonitrile and analyzed via high
performance metabolic profiling involving liquid chromatography
and Fourier Transform ion cyclotron resonance mass spectrom-
etry (LC-FTMS). Employing a column switching technique that
utilizes both anion exchange and reverse phase chromatography,
coupled to FTMS, more than 2,100 mitochondrial metabolites
were identified. Statistical analysis using false discovery rates
revealed more than 200 m/z that distinguish male and female
mitochondrial fractions. Partial least squares discriminant analysis
indicated that over 100 m/z contributed to differences between
mitochondria from wild-type (WT) and thioredoxin-2 transgenic
(TG). The results suggest that implementation of this procedure
could provide a useful hypothesis generating approach to identify
mitochondrial metabolic pathways contributing to toxicity or
disease pathogenesis. The large number of m/z not represented by
chemicals in the metabolomics databases also raises the possibility
that unidentified metabolic processes exist in the mitochondria.
Materials and Methods
Animals and liver harvest
All procedures involving animals were approved by the
Institutional Animal Care and Use Committee of Emory
University and were performed in accordance with published
National Institutes of Health guidelines. A total of 40 animals (wild
type (n=20); Trx2Tg (n=20)) were used in this study and were
separated into groups (n=5) based on sex (male; female), age
(,6 mo; .12 mo) and genotype (WT; TG). Mice were anesthe-
tized with CO2 and euthanized via cervical dislocation. The liver
was excised immediately and placed into homogenization buffer
(22 mM mannitol, 70 mM sucrose, 2 mM Hepes (pH 7.4), 1 mM
EGTA). Mitochondria were isolated by differential centrifugation
using a method adapted from Savage et al. [21]
Sample preparation and extraction
After isolation of mitochondria a small aliquot was used in the
determination of the protein content via BCA assay. To ensure
that equivalent amounts of mitochondria would be analyzed, a
sample corresponding to 250 mg of mitochondrial protein was
used and diluted to a final volume of 50 ml using incubation buffer
(250 mM sucrose, 10 mM MOPS, 3 mM potassium phosphate,
5 mM succinate and 5 mM malate (pH 7.4)). A standard mix
consisting of 14 stable isotopic chemicals that represent a broad
range of chemical properties was added to each sample prior to
extraction and analysis as per Soltow et al. [20]. Metabolites were
extracted by adding 100 ml of acetonitrile to each 50 ml sample
and vortexed to mix. The precipitated protein was pelleted via
centrifugation and the supernatant was used for metabolic
profiling.
LC-FTMS metabolic profiling
Details of the high performance metabolic profiling method
have been published [10,20]. Briefly, mitochondrial extracts in
acetonitrile were separated on either a C18-reverse phase column
or strong anion exchange column [20]. The eluate from the HPLC
separation was connected to a Thermo LTQ-FT mass spectrom-
eter (Thermo Fisher Scientific, San Jose, CA). Analyses were
performed using the MS
1 mode scanning from a m/z range of 85–
850 in the FT detector at a resolution of 50,000 with the wide
range scan mode and 3 million ions per scan. The maximum ion
injection time was 500 ms. Each sample was run in duplicate with
a1 0mL injection volume on each column, taking approximately
one hour to analyze each sample in quadruplicate.
Data collection, processing and analysis
Data were collected as described by Johnson et al. Data were
processed using the R package apLCMS [22]. To determine if an
m/z feature was a mitochondrial metabolite or a buffer
component, buffer only samples were analyzed and a sample-to-
buffer ratio (s/b) (ratio of sample m/z to corresponding m/z in
buffer sample) was calculated. A specific m/z was categorized as a
mitochondrial metabolite if it was found only in the mitochondrial
sample or if s/b $4. False discovery rate (FDR) and orthogonal
partial least squares – discriminant (OPLS-DA) analyses were
performed using 1,485 m/z from anion exchange column and
1,111 m/z from C18 column. FDR [23,24] was performed using
MATLAB to identify m/z to discriminate between two groups. For
OPLS-DA, variation not correlated to classification was removed
with orthogonal signal correction (OSC) using Pirouette software
(Infometrix, Bothell, WA) after centering the mean value for each
frequency [25].
Pathway analysis
The pathway mapping was performed by an in-house program.
Our program considers all common derivatives as given by Brown
et al. [26] when comparing m/z values to the theoretical molecular
weights of metabolites. The stringency of such comparison was
guided by a calibration curve on our FTICR spectrometer, which
agrees with the inverse correlation between FTMS resolution and
m/z [27]. This calibration curve indicates accuracy of 10 ppm at
about 300 m/z, while less accuracy at higher m/z. The data for
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways
and compounds were retrieved from the KEGG FTP site
(retrieved on April 26, 2011). The KEGG human metabolic
pathways contain 1486 metabolites. The visualization of the
mapped compounds on KEGG metabolic map is performed via
the ‘‘Color Pathway’’tool in KEGG Mapper (http://www.
genome.jp/kegg/tool/color_pathway.html).
Results
Study design and metabolite distribution
To study the spectrum of metabolites localized to mitochondria
and to analyze any phenotypic differences attributed to age, sex or
genotype, we isolated mitochondria from WT and TG mice
Figure 1. A breakdown of the animals used for mitochondrial
isolation and metabolic profiling studies. A total of 40 animals
were used, 20 wild type and 20 thiroredoxin-2 transgenic (Trx2TG).
These groups were further broken down into subgroups of 5 based on
age and sex.
doi:10.1371/journal.pone.0033020.g001
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aged less than 6 months or greater than 12 months were analyzed.
After isolation, metabolites were extracted using acetonitrile
(ACN) and analyzed via LC-FTMS. After processing with
apLCMS, anion exchange chromatography (AE) resolved 2872
m/z and reverse phase (C18) chromatography resolved 2754 m/z.
Samples of the mitochondrial isolation buffer were also
analyzed to discern what m/z corresponded to actual mitochon-
drial metabolites and buffer components. A ratio of sample ion
intensity to buffer ion intensity for each m/z was calculated
(Figure 2). Metabolites with a ratio (s/b) $4 were considered to be
mitochondrial and not buffer contaminants. This additional
processing resulted in 1484 and 1110 m/z for AE and C18
respectively. Greater than 70% of the m/z had s/b ,4
(Figure 2A&B); therefore, it is probable that the total number of
mitochondrial metabolites assigned in this study is an underesti-
mation. Additionally, the data from the AE and C18 columns were
compared to determine what mitochondrial m/z were common for
both chromatographic techniques (Figure 2C). This analysis
showed that 467 m/z were common for both AE and C18, while
1017 and 643 were unique for AE and C18 respectively. Together,
these results show that this high performance metabolic profiling
technique resolved 2127 unique m/z.
Results of metabolic pathway analysis and feature
annotation
Mitochondria are involved in many metabolic pathways, such
as oxidative phosphorylation, TCA cycle, fatty acid metabolism
and amino acid oxidation. To test whether the mitochondrial m/z
mapped to metabolic pathways, we used KEGG pathway analysis
to investigate. The human KEGG pathways contain 1486 specific
metabolites. Analyses showed that 745 m/z from AE and C18
matched known KEGG metabolites. Of these, at least one
metabolite mapped to 136 of the 154 possible KEGG pathways.
It should be noted, however, that, of these 745 m/z, many can be
considered as ‘benchmark’ metabolites and can be present in
multiple pathways. The 10 pathways that received the most
matches are shown in Figure 3 and included arachidonic acid,
amino sugar, nucleotide and steroid metabolism.
To further annotate the data, m/z were analyzed for matches
within 10 ppm with the Madison Metabolomics Consortium
Database (MMCD) and Metlin databases. These databases
contain information regarding the identification of specific
molecules according to their m/z and common ionic forms, e.g.
proton ([M+H]), sodium ([M+Na]), and acetonitrile ([M+ACN
+H]) adducts. Identities of some m/z matches to metabolomics
databases were confirmed using internal standards, including
amino acids and a relatively small number of nutrients, dietary
compounds, intermediary metabolites and environmental com-
pounds. For example, the identity of glucose, methionine,
glutamate and tyrosine were all confirmed by m/z and retention
time matching to stable isotopic controls. Because confirmation of
identity of the total number of metabolites was not feasible, we
used bioinformatic methods to test for differences according to sex,
genotype and age.
Figure 2. Distribution of metabolites resolved by anion
exchange (A) and reverse phase (B) chromatography. To
determine if a metabolite was present in the mitochondrial isolation
and not a buffer contaminant, a ratio of ion intensity (sample ion
intensity/buffer ion intensity) was calculated for each metabolite. A
metabolite was determined to be ‘‘mitochondrial’’ if this ratio (s/b) was
greater than or equal to 4. Additionally, employment of two
chromatographic techniques resulted in the detection of 2127
mitochondrial metabolites (C).
doi:10.1371/journal.pone.0033020.g002
Figure 3. Most metabolic pathways are represented in
metabolites isolated from liver mitochondria. Ten pathways
containing the most matches are plotted.
doi:10.1371/journal.pone.0033020.g003
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False discovery rate analysis (FDR) is an extension of a
Bonferroni-type, multiple comparison procedure that is used to
determine what m/z contribute significantly to discriminate
groups. Therefore, FDR was employed to determine if mitochon-
drial metabolic profiles were significantly different between males
vs. females, WT vs. TG, and young vs. old. Because of the
discovery/exploratory nature of these studies, the q-value was set
at 0.1. FDR did not show significance due to age (,6 mo. vs.
$12 mo.) or genotype (WT vs. TG). However, a significant
difference was observed due to sex. This analysis showed that 246
m/z from AE and 211 m/z from C18 distinguished male
mitochondria from female mitochondria (Table S1A&B). Briefly,
putative identification of these m/z included amino acids,
dipeptides, tripeptides, nucleotides and a number of other known
and unknown metabolites.
Ofthe246 AEm/z foundtodistinguishmalefromfemale,197m/z
had greater ion intensity in male mitochondria while 49 had greater
intensity in females. A sample of 3 m/z with greater ion intensity in
males (Figure 4A–C) includes amino acids, leucine/isoleucine,
glutamate, and methionine. Sample metabolites with greater ion
intensity in females (Figure 4D–E) include adenosine, amino
octadecanoic acid and an unknown metabolite (m/z: 537.789).
FDR also determined that 211 m/z, resolved using C18,
distinguished male from female mitochondria. 178 m/z had
greater ion intensity in male mitochondria and 33 had greater ion
intensity in female mitochondria. Figure 5 shows a sample of 6 m/z
that had greater ion intensity in either males or females.
Figure 4. Mitochondrial metabolites from AE that were found to discriminate male from female mitochondria using false discovery
rate analysis (q=0.1). Metabolites with greater ion intensity in male mitochondria include (A) leucine/isoleucine, (B) glutamate and (C) methionine.
Metabolites with greater ion intensity in female mitochondria include (D) adenosine, (E) amino octadecanoic acid and (F) unknown metabolite (m/z
537.789). Data was analyzed using one-way ANOVA and Tukey’s post hoc test (* p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0033020.g004
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isoleucine, glutamate, and methionine (Figure 5A–C). Addition-
ally, similar to that of AE, adenosine had higher ion intensity in
females along with sphinganine and an unknown metabolite (m/z;
442.759) (Figure 5D–F).
Partial least squares discriminant analysis shows
significant difference between WT and TG
We used partial least squares discriminant analysis with
orthogonal signal correction (OPLS-DA) to further evaluate
whether metabolic differences between WT and TG mice could
be detected. Score plots of the OPLS-DA results show that data for
both AE (Figure 6A) and C18 (Figure 6B) clustered into two
distinct groups. OPLS-DA of data from AE showed that signals
from 108 m/z contributed to separation while C18 analysis
showed contribution of 136 m/z. Of these 244 m/z, 38 were
common to both chromatographic techniques, resulting in 206
distinguishing m/z. Putative identification of these m/z included
many methylated metabolites and other molecules involved in
methyl group donation. These compounds included methylated
nucleotides, folate and choline (Table S2A&B).
Discussion
Metabolic profiling involves the measurement and character-
ization of metabolites and is typically applied to samples acquired
Figure 5. Mitochondrial metabolites from C18 that were found to discriminate male from female mitochondria using false
discovery rate analysis (q=0.1). Metabolites with greater ion intensity in male mitochondria include (A) leucine/isoleucine, (B) glutamate and (C)
methionine. Metabolites with greater ion intensity in female mitochondria include (D) adenosine, (E) sphinganine and (F) unknown metabolite (m/z
442.759). Data was analyzed using one-way ANOVA and Tukey’s post hoc test (* p,0.05, *** p,0.001).
doi:10.1371/journal.pone.0033020.g005
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However, this current project highlights information that can be
attained by profiling isolated mitochondria. Our method of high
performance metabolic profiling commonly used on plasma
samples was applied to isolated liver mitochondria. Use of a
simple organic extraction and established LC-FTMS protocol with
data extraction by apLCMS resulted in the detection of more than
2,100 mitochondrial metabolites. It is important to note that
greater than 70% of the m/z detected were present in both the
mitochondrial samples and buffer controls. Thus, it is likely that
this number of mitochondrial metabolites is an underestimation
due to the natural occurrence of the buffer components in
mammalian cells, such as succinate, malate and various 6-carbon
carbohydrates. It is important to additionally note that the
mitochondrial preparation is primarily mitochondria but also
contains lysosomes and peroxisomes. Some of the metabolites may
be unique to these organelles, but fractionation studies were not
pursued because of the likelihood of artifactual metabolite loss due
to additional manipulations required for separation.
KEGG is a widely used compendium of biological pathways
that consists of genomic, chemical, and network information with
cross references to outside databases [28,29]. Using KEGG
pathway analysis, we found that at least one mitochondrial
metabolite mapped to over 88% (136/154) of the KEGG
pathways. Importantly, the pathways that had the greatest number
of matches were also known to involve the mitochondria. For
example, 22 and 21 metabolites mapped to steroid biosynthesis
and steroid hormone biosynthesis, respectively. This is important
because the rate limiting step in steroid biosynthesis is transport of
cholesterol into the mitochondria for the conversion of cholesterol
to pregnenolone [30]. Also, porphyrin metabolism came up with
the fourth most hits and four of the eight steps involved in heme
biosynthesis take place in the mitochondrion [31]. Of general
importance, this pathway data demonstrates that mitochondria
contain metabolites from the majority of cellular metabolic
pathways.
Unsupervised statistical analyses comparing sex, age or
genotype uncovered only a sex phenotype. FDR analysis provided
Figure 6. OPLS-DA score plot results comparing WT vs. TG mitochondrial metabolites from (A) AE and (B) C18. WT (red) and TG (blue).
doi:10.1371/journal.pone.0033020.g006
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mitochondria had greater ion intensities for amino acids when
compared to females. Lamont and colleagues reported gender
differences in amino acid metabolism in mitochondria from
skeletal muscle. They found that, during exercise, females relied
more on fat as an energy source where males utilized amino acid
oxidation [32,33]. Additionally, estrogen enhances transcription of
genes encoded by mitochondrial DNA, resulting in an increase in
the functional capacity of female mitochondria and may
potentially protect young females from b-amyloid toxicity
[34,35,36]. Taken together, the data show that use of high
performance metabolic profiling is suitable for discovery of
phenotypic differences in mitochondrial metabolism.
While a significant difference was not detected when WT and
TG mitochondria were compared using FDR, the supervised test,
OPLS-DA, was successful in identifying 206 m/z that distinguish
the mitochondria. Putative identification of these m/z, such as
tetrahydrofolate 10-formyldihydrofolate and cytidine monophos-
phate, revealed a number of molecules involved in choline
metabolism and purine and pyrimidine metabolism. These data
indicate a possible phenotype involving methylation pathways.
Supporting this phenotype, unpublished proteomic data from our
laboratory (Y-M Go, unpublished) comparing protein expression
in WT versus TG mice showed differences in expression of
sarcosine dehydrogenase and betaine-homocysteine methyltrans-
ferase. Sarcosine dehydrogenase converts monomethyl-glycine to
glycine and betaine-homocysteine methyltransferase transfers a
methyl group from trimethyl-glycine to homocysteine, producing
methionine and dimethyl-glycine. Both of these enzymes are
involved in the catabolism of choline and glycine [37]. Alterations
in metabolic profiles have also been observed in other studies
involving transgenic animals. For example, Manna and colleagues
showed that PPAR-a null mice, when exposed to ethanol, had an
increased amount of indole-3-lactone in the urine [38]. Also, a
metabolomic comparison of three different transgenic models of
Huntington’s disease (HD) revealed that all three models shared
four common metabolites that were indicative of the HD
phenotype [39].
Conclusion
The data presented in this manuscript demonstrate that high
performance metabolic profiling can be applied to isolated
mitochondria to discover metabolic phenotypes that might be
difficult to discern by targeted approaches. The KEGG pathway
analyses show that mitochondria contain metabolites from a
majority of cellular metabolic pathways. Statistical comparisons of
the samples based on sex, age and genotype show that both sex
and the over-expression of the mitochondrial protein, Trx2, result
in a distinct phenotype. Additionally, the large number of
unidentified m/z in the mitochondrial preparations implicate
several different possibilities, such as the presence of metabolic
pathways yet to be described or an extensive accumulation of
environmental chemicals, some of which could be retained
because of their lipophilic, cationic nature and no effective
elimination pathways. This would suggest a need to further
examine detoxification functions of mitochondrial cytochrome
P450 enzymes. These pathways would be of particular importance
under pathologic conditions, such as alcohol abuse, where GSH
metabolism is impaired. With this in mind, the results suggest that
this approach could be valuable in hypothesis development and
discovery of new mechanisms and biomarkers involved in
mitochondrial dysfunction, such as profiling human fibroblasts
from infants with unidentified disorders or as a diagnostic tool for
inborn errors of metabolism.
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